Ka Pipeline

Hoʻokumu ʻia ka R&D o Sorrento i ka hoʻokele ʻana i nā mea hou i COVID-19, ka mālama ʻana i ka maʻi kanesa, ka hoʻomalu ʻeha piha a me nā maʻi autoimmune.

Nā Papahana Nui Hōʻike Hoʻokumu Wā I I Māhele II Māhele III/Pivotal Hōʻailona FDA
Nā Polokalamu COVID-19  

COVISTIX™ (ʻike maʻi) Hoʻāʻo Antigen wikiwiki

*

ʻO ka mana hoʻohana pilikia (EUA) ma Mexico (COFEPRIS), Brazil (ANVISA), a me CE Marked ma ʻEulopa

COVIMARK™ (ʻike maʻi) Hoʻāʻo Antigen wikiwiki

*

Hoʻouna ʻia ka palapala noi ma US a me Kanada no ka ʻae ʻana i ka hoʻohana ʻana i ka pilikia (EUA)

VIREX (ʻike maʻi) Ma ka Home Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (Lapaʻau) Neutralizing Antibody (IV) i nā maʻi ma waho a me nā maʻi maʻi

20%*

FUJOVEE™ (Abivertinib) ʻO COVID-19 koʻikoʻi i loko o nā maʻi ICU

82%*

Ho'āʻo Pivotal e kali ana i ka hoʻomaʻemaʻe FDA

OQORY™ (COVI-MSC) ARDS ma muli o COVID-19 i loko o nā maʻi ICU

82%*

Hoʻokolokolo Pivotal ma Brazil

Me kākoʻo ana Mea kāohi (palapala waha) Anti-viral

40%*

Omicron mRNA Vaccine laʻau koʻokoʻo

20%*

Nā Papahana Nui Hōʻike Hoʻokumu Wā I I Māhele II Māhele III/Pivotal Hōʻailona FDA
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) ʻO nā Lymphoma pūnaewele B

60.2%*

FUJOVEE™ (Abivertinib) Hoʻomākaukau

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*Ma ka hui pū ʻana me Lee's Pharm ma Kina

PD-L1 (STI-3031)** ʻĀmaʻomaʻo Cervical

82%*

** Ma US a me ka hui pū ʻana me ImmuneOncia ma Korea

CD47 Nā Puolo Paʻa

40%*

CD38 DAR-T Ka Myeloma Maha

40%*

CD38 ADC Amyloidosis, Myeloma Nui, T-ALL, a me ka esophageal

40%*

ʻO ka maʻi oncolytic Seprehvec™ Nā Tumors Paʻa; ʻO nā puʻupuʻu CNS

40%*

BCMA ADC Nā ʻōpū wai

20%*

Bevacizumab-ADNAB™ ʻO ke Kanesa Endometrial

40%*

Ma ka hui pū ʻana me Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Cancer

40%*

Ma ka hui pū ʻana me Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Ma ka hui pū ʻana me Mayo Clinic

Sofusa® kūʻē i ka PD-1 ʻO Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Nā Papahana Nui Hōʻike Hoʻokumu Wā I I Māhele II Māhele III/Pivotal Hōʻailona FDA
Pain  

ZTlido® 1.8%
Neuralgia Postherpetic - PHN

99.8%*

Gloperba®
Lapaʻau ʻana i ka gout (waha)

99.8%*

SEMDEXA (SP-102) ʻEha Lumbar Radicular/Sciatica

82%*

SP-103 (Lidocaine Topical System 5.4%) ʻEhaʻeha ʻeha

60.2%*

SP-104 (Naltrexone Hoʻopaneʻe ʻia ʻo Burst Low Dose) Fibromyalgia

20%*

RTX (resiniferatoxin)
ʻAi ʻana i ka epidural
ʻEha Intractable in Advanced Cancer

60.3%*

Ka inoa keiki makua ole

RTX (resiniferatoxin)
Alahele intra-articular
ʻO ka ʻeha OA o nā kuli ma ke ʻano haʻahaʻa

60.2%*

Nā Papahana Nui Hōʻike Hoʻokumu Wā I I Māhele II Māhele III/Pivotal Hōʻailona FDA
Ka Laau Laau Lymphatic  

Sofusa® kūʻē i ka TNF ʻAiʻi (RA)

40%*

Sofusa® kūʻē i ka PD-1 ʻO Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® kūʻē iā CTLA-4 Melanoma

40%*

Ma ka hui pū ʻana me Mayo Clinic
Nā Polokalamu COVID-19
Nā Papahana Nui (Hōʻike) Māhele
COVISTIX™ (ʻike maʻi) FDA EUA
COVIMARK™ (ʻike maʻi) FDA EUA
VIREX (ʻike maʻi) PH III
COVISHIELD™ (Lapaʻau) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Me kākoʻo ana Ka mea hoʻopaʻa (palapala waha) Ph II
Omicron mRNA Vaccine Hoʻokumu
immunotherapy
Nā Papahana Nui (Hōʻike) Māhele
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Hoʻokumu
FUJOVEE™ (Abivertinib) Hoʻokumu
FUJOVEE™ (Abivertinib) Hoʻokumu
FUJOVEE™ (Abivertinib) Hoʻokumu
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Nā Tumors Paʻa) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, a me ka esophageal) Ph I
ʻO ka maʻi oncolytic Seprehvec™ (Nā ʻōpū paʻa; nā ʻōpū CNS) PH I
BCMA ADC (Liquid Tumors) Hoʻokumu
Bevacizumab-ADNAB™ (Ka maʻi maʻi endometrial) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® kūʻē i ka PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Pain
Nā Papahana Nui (Hōʻike) Māhele
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Hōʻailona FDA
Gloperba® 1.8% Lapaʻau ʻana i ka gout (waha) Hōʻailona FDA
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Naltrexone Hoʻopaneʻe ʻia ʻo Burst Low Dose) Hoʻokumu
RTX (resiniferatoxin) ʻAi ʻana i ka epidural Ph II
RTX (resiniferatoxin) Alahele intra-articular Ph II
Hoʻouna Lymphatic
Nā Papahana Nui (Hōʻike) Māhele II
Sofusa® kūʻē i ka TNF (Autoimmune RA) Ph I
Sofusa® kūʻē i ka PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® kūʻē iā CTLA-4 (Melanoma) Ph I